Skip to main content
. Author manuscript; available in PMC: 2023 Nov 8.
Published in final edited form as: Immunity. 2022 Oct 25;55(11):2044–2058.e5. doi: 10.1016/j.immuni.2022.10.002

Figure 3. IRF8 in TAMs drives a broad antigen presenting cell gene expression program.

Figure 3.

(A) Average z-score of genes significantly downregulated in TAMs sorted from tumors of Irf8fl/flPyMT and CD11cCreIrf8fl/flPyMT mice. RNA was extracted and sequenced. Genes were grouped based on cell localization and function, excluding genes with unknown functions, pseudogenes and noncoding RNAs (BC035044, BC064078, F630111L10Rik, Gm32014, 2610035D17Rik, and A630012P03Rik).

(B) CDF plot displaying enrichment of IRF8-activated gene signatures in PyMT tumor DC1 (green), DC2 (orange), monocyte (pink), MTM (blue) and TAM (red). (C) Ingenuity Pathway Analysis among differentially expressed genes between Irf8fl/fl and CD11cCreIrf8fl/fl TAMs. Most significantly enriched pathways in Irf8fl/fl TAMs are shown.

See also Figure S3 and Tables S2–3.